{
    "Rank": 135,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00727441",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "J0810"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA006973",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA006973"
                        },
                        {
                            "SecondaryId": "J0810"
                        },
                        {
                            "SecondaryId": "CDR0000600355"
                        },
                        {
                            "SecondaryId": "NA_00015858",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "JHM IRB"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery",
                "OfficialTitle": "A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas"
            },
            "StatusModule": {
                "StatusVerifiedDate": "February 2020",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 2, 2008",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 2015",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 2019",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "August 1, 2008",
                "StudyFirstSubmitQCDate": "August 1, 2008",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "August 4, 2008",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "May 16, 2019",
                "ResultsFirstSubmitQCDate": "May 16, 2019",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "June 5, 2019",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "February 12, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "February 25, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine therapy together with cyclophosphamide may kill more tumor cells. It is not yet known whether vaccine therapy is more effective with or without cyclophosphamide in treating patients with pancreatic cancer.\n\nPURPOSE: This randomized clinical trial is studying the side effects of vaccine therapy and to see how well it works when given with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nTo evaluate the safety and feasibility of a GVAX pancreatic cancer vaccine (GM-CSF gene-transfected allogeneic pancreatic cancer vaccine) when administered alone or in combination with a single intravenous dose or daily metronomic oral doses of cyclophosphamide as neoadjuvant and adjuvant treatment in patients with resectable stage I or II adenocarcinoma of the head, neck, or uncinate process of the pancreas.\nTo assess the immune cell infiltrates, particularly T-regulatory cells (Tregs) and CD4+ and CD8+ effector T cells, after neoadjuvant GVAX pancreatic cancer vaccination.\nTo assess the changes in the number and function of peripheral mesothelin-specific CD8+ T cells and CD4+, FoxP3+, and GITR+ Tregs after each GVAX pancreatic cancer vaccination when administered alone or in combination with a single dose or metronomic doses of cyclophosphamide.\n\nSecondary\n\nTo estimate disease-free and overall survival of patients treated with these regimens.\nTo estimate the effect of immune parameters on disease-free and overall survival of these patients.\n\nOUTLINE: Patients are randomized to 1 of 3 treatment arms.\n\nArm A: Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 courses.\nArm B: Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses.\nArm C: Patients receive GVAX pancreatic cancer vaccine ID on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 courses.\n\nPatients undergo blood sample collection periodically for correlative laboratory studies, including immune cell analysis. Immune cell analysis includes monitoring the quantitative change of peripheral blood lymphocytes, including regulatory T cells (Tregs), and functional analysis of T-cell immune response. Tumor tissue samples collected at the time of surgery are analyzed for tumor antigens and infiltrating immune cells by immunohistochemistry and quantitative real-time PCR.\n\nAfter completion of study treatment, patients are followed periodically."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Pancreatic Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "adenocarcinoma of the pancreas",
                        "stage I pancreatic cancer",
                        "stage II pancreatic cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "87",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Arm A",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: GVAX pancreatic cancer vaccine"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Arm B",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: GVAX pancreatic cancer vaccine",
                                    "Drug: cyclophosphamide"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Arm C",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: GVAX pancreatic cancer vaccine",
                                    "Drug: cyclophosphamide"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "GVAX pancreatic cancer vaccine",
                            "InterventionDescription": "Given intradermally",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Arm A",
                                    "Arm B",
                                    "Arm C"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "cyclophosphamide",
                            "InterventionDescription": "Given IV (Arm B), given orally (Arm C)",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Arm B",
                                    "Arm C"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Safety as Measured by Number of Participants With Treatment-related Grade 3 or 4 Local and Systemic Toxicity as Defined by NCI CTCAE v3.0",
                            "PrimaryOutcomeTimeFrame": "7 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Amount of T-regulatory Cells (Tregs) and CD4+ and CD8+ Effector T Cells, After Neoadjuvant GVAX Pancreatic Cancer Vaccination.",
                            "PrimaryOutcomeTimeFrame": "up to 8 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",
                            "PrimaryOutcomeDescription": "Change in the number and function of peripheral mesothelin-specific CD8+ T cells and CD4+, FoxP3+, and GITR+ Tregs after each GVAX pancreatic cancer vaccination when administered alone or in combination with a single dose or metronomic doses of cyclophosphamide.",
                            "PrimaryOutcomeTimeFrame": "up to 8 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Overall Survival",
                            "SecondaryOutcomeDescription": "OS will be measured from date of randomization until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.",
                            "SecondaryOutcomeTimeFrame": "10 years and 7 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Disease Free Survival",
                            "SecondaryOutcomeDescription": "Disease free survival is defined as the time interval from the date of randomization to the date of radiographic evidence of disease recurrence. Estimation based on the Kaplan-Meier curve.",
                            "SecondaryOutcomeTimeFrame": "10 years and 7 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nNewly diagnosed adenocarcinoma of the head, neck, or uncinate process of the pancreas\n\nStage I or II disease\n\nSurgically resectable disease (R0 or R1) by spiral CT scan\n\nNo distant metastases\nA clear fat plane is present around the celiac and superior mesenteric arteries\nPatent superior mesenteric and portal veins\nCandidate for a pancreaticoduodenectomy\n\nPATIENT CHARACTERISTICS:\n\nECOG performance status 0-1\nHemoglobin \u2265 9 g/dL\nANC \u2265 1,500/mm\u00b3\nPlatelet count \u2265 100,000/mm\u00b3\nSerum creatinine \u2264 2 mg/dL\nAST and ALT \u2264 2 times upper limit of normal (ULN)\nAmylase \u2264 2 times ULN\nAlkaline phosphatase \u2264 5 times ULN\nHyperbilirubinemia secondary to tumor-associated extrahepatic biliary obstruction allowed\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception during and for \u2265 4 weeks after the completion of study treatment\nNo history of autoimmune disease, including systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis\nNo uncontrolled medical problems\nNo active infections\nNo other cancer within the past 5 years except for superficial bladder cancer, nonmelanoma skin cancer, or low-grade prostate cancer not requiring therapy\n\nPRIOR CONCURRENT THERAPY:\n\nMore than 28 days since prior anticancer therapy\nNo prior cancer immunotherapy, including the same pancreatic cancer vaccine used in this study\nMore than 28 days since prior systemic steroid therapy or immunosuppressive therapy\nNo systemic steroid therapy or immunosuppressive therapy during and within 28 days after vaccine administration\nNo other concurrent immunotherapy, chemotherapy, radiotherapy, gene therapy, biologic therapy, or investigational therapy for the treatment of pancreatic cancer",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Daniel A. Laheru, MD",
                            "OverallOfficialAffiliation": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "LocationCity": "Baltimore",
                            "LocationState": "Maryland",
                            "LocationZip": "21231-2410",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                            "FlowGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                        },
                        {
                            "FlowGroupId": "FG001",
                            "FlowGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                            "FlowGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given IV"
                        },
                        {
                            "FlowGroupId": "FG002",
                            "FlowGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                            "FlowGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given orally"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "29"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "28"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "30"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "11"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "6"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "22"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG002",
                                                    "FlowAchievementNumSubjects": "25"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Disease Progression",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "11"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "14"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "17"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Eligibility",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "7"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "5"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "7"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Death",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Physician Decision",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG002",
                                                    "FlowReasonNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                            "BaselineGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                        },
                        {
                            "BaselineGroupId": "BG001",
                            "BaselineGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                            "BaselineGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)"
                        },
                        {
                            "BaselineGroupId": "BG002",
                            "BaselineGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                            "BaselineGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral (PO) cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)"
                        },
                        {
                            "BaselineGroupId": "BG003",
                            "BaselineGroupTitle": "Total",
                            "BaselineGroupDescription": "Total of all reporting groups"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "29"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG001",
                                        "BaselineDenomCountValue": "28"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG002",
                                        "BaselineDenomCountValue": "30"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG003",
                                        "BaselineDenomCountValue": "87"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "17"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "15"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "12"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "44"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "12"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "13"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "18"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "43"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "62.79",
                                                                "BaselineMeasurementSpread": "10.83"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "64.96",
                                                                "BaselineMeasurementSpread": "11.73"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "67.97",
                                                                "BaselineMeasurementSpread": "9.96"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "65.28",
                                                                "BaselineMeasurementSpread": "10.93"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "9"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "12"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "16"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "37"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "20"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "16"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "14"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "50"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "3"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "27"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "24"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "30"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "81"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "1"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "1"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "25"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "26"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "28"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "79"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "0"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "2"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "1"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG003",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Safety as Measured by Number of Participants With Treatment-related Grade 3 or 4 Local and Systemic Toxicity as Defined by NCI CTCAE v3.0",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "7 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given orally"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "29"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "2"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Amount of T-regulatory Cells (Tregs) and CD4+ and CD8+ Effector T Cells, After Neoadjuvant GVAX Pancreatic Cancer Vaccination.",
                            "OutcomeMeasurePopulationDescription": "Data was not collected for this outcome measure.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "up to 8 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given orally"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",
                            "OutcomeMeasureDescription": "Change in the number and function of peripheral mesothelin-specific CD8+ T cells and CD4+, FoxP3+, and GITR+ Tregs after each GVAX pancreatic cancer vaccination when administered alone or in combination with a single dose or metronomic doses of cyclophosphamide.",
                            "OutcomeMeasurePopulationDescription": "Data was not collected for this outcome measure.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "up to 8 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given orally"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "0"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Overall Survival",
                            "OutcomeMeasureDescription": "OS will be measured from date of randomization until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "10 years and 7 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Arm A",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Arm B",
                                        "OutcomeGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)"
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Arm C",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "29"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "34.2",
                                                                "OutcomeMeasurementLowerLimit": "21.6",
                                                                "OutcomeMeasurementUpperLimit": "45.7"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "15.4",
                                                                "OutcomeMeasurementLowerLimit": "13.2",
                                                                "OutcomeMeasurementUpperLimit": "26.5"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "16.5",
                                                                "OutcomeMeasurementLowerLimit": "11.3",
                                                                "OutcomeMeasurementUpperLimit": "25.2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Disease Free Survival",
                            "OutcomeMeasureDescription": "Disease free survival is defined as the time interval from the date of randomization to the date of radiographic evidence of disease recurrence. Estimation based on the Kaplan-Meier curve.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "10 years and 7 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally"
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given IV"
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                                        "OutcomeGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\nCyclophosphamide: Given orally"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "29"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "28"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "18.92",
                                                                "OutcomeMeasurementLowerLimit": "13.87",
                                                                "OutcomeMeasurementUpperLimit": "34.1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "8.54",
                                                                "OutcomeMeasurementLowerLimit": "2.66",
                                                                "OutcomeMeasurementUpperLimit": "17.1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "5.56",
                                                                "OutcomeMeasurementLowerLimit": "3.67",
                                                                "OutcomeMeasurementUpperLimit": "14.0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventsTimeFrame": "Up to 8 years",
                "EventsDescription": "Adverse events were collected through protocol defined mechanisms (i.e. regular investigator assessments and regular laboratory testing)",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Arm A - GVAX Vaccine Without Cyclophosphamide",
                            "EventGroupDescription": "Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "29",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "29",
                            "EventGroupOtherNumAffected": "29",
                            "EventGroupOtherNumAtRisk": "29"
                        },
                        {
                            "EventGroupId": "EG001",
                            "EventGroupTitle": "Arm B - GVAX Vaccine With IV Cyclophosphamide",
                            "EventGroupDescription": "Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)",
                            "EventGroupDeathsNumAffected": "1",
                            "EventGroupDeathsNumAtRisk": "28",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "28",
                            "EventGroupOtherNumAffected": "28",
                            "EventGroupOtherNumAtRisk": "28"
                        },
                        {
                            "EventGroupId": "EG002",
                            "EventGroupTitle": "Arm C - GVAX Vaccine With PO Cyclophosphamide",
                            "EventGroupDescription": "Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.\n\nGVAX pancreatic cancer vaccine: Given intradermally\n\ncyclophosphamide: Given IV (Arm B), given orally (Arm C)",
                            "EventGroupDeathsNumAffected": "1",
                            "EventGroupDeathsNumAtRisk": "30",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "30",
                            "EventGroupOtherNumAffected": "30",
                            "EventGroupOtherNumAtRisk": "30"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventNotes": "and administration site conditions",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventNotes": "and administration site conditions",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fever",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventNotes": "and administration site conditions",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Lymphocyte count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "White blood cell count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blister, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Skin hyperpigmentation, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Erythema, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "29",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "28",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Induration, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "29",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "26",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "30",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "24",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "23",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "24",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Tenderness, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "23",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "18",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hives",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vaccine site flare",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Warmth, vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "29"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "17",
                                        "OtherEventStatsNumAtRisk": "28"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG002",
                                        "OtherEventStatsNumAffected": "17",
                                        "OtherEventStatsNumAtRisk": "30"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Daniel Laheru",
                    "PointOfContactOrganization": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "PointOfContactEMail": "laherda@jhmi.edu",
                    "PointOfContactPhone": "410-955-8974"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000010190",
                            "ConditionMeshTerm": "Pancreatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004701",
                            "ConditionAncestorTerm": "Endocrine Gland Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000010182",
                            "ConditionAncestorTerm": "Pancreatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004700",
                            "ConditionAncestorTerm": "Endocrine System Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M3275",
                            "ConditionBrowseLeafName": "Adenocarcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12800",
                            "ConditionBrowseLeafName": "Pancreatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7553",
                            "ConditionBrowseLeafName": "Endocrine Gland Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12792",
                            "ConditionBrowseLeafName": "Pancreatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7552",
                            "ConditionBrowseLeafName": "Endocrine System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4387",
                            "ConditionBrowseLeafName": "Pancreatic Cancer",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC19",
                            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000003520",
                            "InterventionMeshTerm": "Cyclophosphamide"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000007166",
                            "InterventionAncestorTerm": "Immunosuppressive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000018501",
                            "InterventionAncestorTerm": "Antirheumatic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018906",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
                        },
                        {
                            "InterventionAncestorId": "D000000477",
                            "InterventionAncestorTerm": "Alkylating Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000019653",
                            "InterventionAncestorTerm": "Myeloablative Agonists"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2986",
                            "InterventionBrowseLeafName": "Gemcitabine",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M8290",
                            "InterventionBrowseLeafName": "Fluorouracil",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M6417",
                            "InterventionBrowseLeafName": "Cyclophosphamide",
                            "InterventionBrowseLeafAsFound": "Time",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M377",
                            "InterventionBrowseLeafName": "Capecitabine",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M22244",
                            "InterventionBrowseLeafName": "Pancrelipase",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M12804",
                            "InterventionBrowseLeafName": "Pancreatin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9902",
                            "InterventionBrowseLeafName": "Immunosuppressive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20294",
                            "InterventionBrowseLeafName": "Antirheumatic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20632",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3510",
                            "InterventionBrowseLeafName": "Alkylating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Gast",
                            "InterventionBrowseBranchName": "Gastrointestinal Agents"
                        }
                    ]
                }
            }
        }
    }
}